Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T20:33:07.117Z.
Calculation as of: 2026-10-06T20:33:07.117Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 35a271d61501d442ff1d5238fcf80e89d6bdfa5e87b371fe53e06a7cba571f48
PE RATIO
N/A
Market Cap
$531.98M
PE Ratio
1185.38
TTM Avg
806.49
3Y Avg
715.80
5Y Avg
715.80
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | $529.58M | N/A | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $531.52M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $531.98M | 1185.38 | 806.49 | 715.80 | 715.80 |
| Monopar Therapeutics Inc. (MNPR)vs › | $533.04M | N/A | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $524.43M | N/A | N/A | N/A | N/A |
| ProKidney Corp. (PROK)vs › | $538.01M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $519.25M | N/A | 0.20 | 0.20 | 0.20 |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $516.76M | N/A | N/A | N/A | N/A |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $548.51M | N/A | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $505.87M | N/A | 12.07 | 12.07 | 12.07 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$5.86
Forward EPS (Est.)
$-0.49
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
